环辛基甲胺 | 4734-81-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环辛基甲胺
• 英文名称: C-cyclooctyl-methylamine
• 英文别名: C-Cyclooctyl-methylamin；(Cyclooctyl-methyl)-amin；Aminomethyl-cyclooctan；cyclooctylmethylamine；Cyclooctylmethylamin；cyclooctylmethanamine
• CAS: 4734-81-0
• 化学式: C₉H₁₉N
• mdl: MFCD00154120
• 分子量: 141.257
• InChiKey: GQOIKWAYFXTZOK-UHFFFAOYSA-N

物化性质

• 沸点：
  194.5±8.0 °C(Predicted)
• 密度：
  0.847±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  环辛基甲胺 在 溶剂黄146 、 sodium nitrite 作用下， 生成 methylcyclooctene
  参考文献：
  名称：

  Ruzicka; Brugger, Helvetica Chimica Acta, 1926, vol. 9, p. 403

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(硝基甲基)环辛烯 在 palladium on activated charcoal 盐酸 、 lithium aluminium tetrahydride 、 氢气 、 三乙胺 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 36.0h， 生成 环辛基甲胺
  参考文献：
  名称：

  1-[（3R，4R）-1-环辛基甲基-3-羟甲基-4-哌啶基] -3-乙基-1,3-二氢苯并咪唑-2-酮的新合成方法（J-113397）非肽ORL-1受体拮抗剂

  摘要：

  一种有效的方法来处理1-[（（3R，4R）-1-环辛基甲基-3-羟甲基-4-哌啶基] -3-乙基-1,3-二氢苯并咪唑-2-酮（J-113397）1，第一个概述了文献中描述的非肽ORL-1受体拮抗剂。通过环辛基甲胺的迈克尔加成物8的Dieckmann环化成丙烯酸甲酯构造哌啶骨架后，与邻苯二胺缩合生成β-烯胺酯2，该酯已被方便地用于在C-4处构建苯并咪唑酮取代基。中间体11的催化加氢反应，然后通过碱促进的关键化合物12的顺式-反式异构化反应，导致形成酯13，该酯通过LiAlH（4）还原转化为外消旋标题化合物。

  DOI：

  10.1016/s0968-0896(01)00085-2

文献信息

• Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20020035137A1

  公开（公告）日：2002-03-21

  Compounds of formula (I) 1 or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP 1 B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  式（I）的化合物或其治疗上可接受的盐是蛋白酪氨酸激酶PTP1B的抑制剂。公开了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Carbostyril derivative
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05227381A1

  公开（公告）日：1993-07-13

  Carbostyril compounds or salts thereof of the formula ##STR1## wherein A is a C.sub.1 -C.sub.6 alkylene group; R.sup.1 is a C.sub.3 -C.sub.8 cycloalkyl-C.sub.1 -C.sub.6 alkyl group which may have, as a substituent, a group selected from the group consisting of C.sub.1 -C.sub.6 alkoxycarbonyl groups, a carboxy group, C.sub.2 -C.sub.6 alkanoyloxy-C.sub.1 -C.sub.6 alkyl groups, amino-C.sub.1 -C.sub.6 alkyl groups, C.sub.1 -C.sub.6 alkylamino-C.sub.1 -C.sub.6 alkyl groups and hydroxy-C.sub.1 -C.sub.6 alkyl groups, a C.sub.3 -C.sub.8 cycloalkyl group, a tetrahydropyranyl-C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.3 alkylenedioxy group-substituted C.sub.1 -C.sub.6 alkyl group, a phenyl-C.sub.1 -C.sub.6 alkyl group having, as a substituent on the phenyl ring, 1 to 3 groups selected from the group consisting of C.sub.1 -C.sub.6 alkyl groups and a hydroxyl group, or a piperidinyl-C.sub.1 -C.sub.6 alkyl group having a C.sub.1 -C.sub.6 alkyl group as a substituent; R.sup.2 is a 5-membered or 6-membered saturated or unsaturated heterocyclic-C.sub.1 -C.sub.6 alkyl group, said heterocyclic being selected from the group consisting of pyrrolidinyl, morpholino, piperidinyl, thiomorpholino, imidazolyl, 1,2,4-triazolyl, furyl, piperazinyl, pyridyl, tetrahydropyranyl and 1,3-oxathiolranyl groups which may have, as a substituent thereon 1 to 3 groups selected from the group consisting of hydroxy-C.sub. 1 -C.sub.6 alkyl groups, C.sub.2 -C.sub.6 alkanoyloxy-C.sub.1 -C.sub.6 alkyl groups, a hydroxyl group, C.sub.1 -C.sub.6 alkyl groups, amino-C.sub.1 -C.sub.6 alkyl groups, C.sub.1 -C.sub.6 alkylamino-C.sub.1 -C.sub.6 alkyl groups, C.sub.1 -C.sub.6 alkoxy groups, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkoxy groups, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkyl groups, a thio group and C.sub.1 -C.sub.6 alkylamido groups; the carbon-carbon bond between the 3- and 4-positions in the carbostyril skeleton being a single bond or a double bond and pharmaceutical compositions containing the compound as the active ingredient.

  碳基喹啉化合物或其盐的化学式为##STR1##其中A为C.sub.1 -C.sub.6烷基链；R.sup.1为C.sub.3 -C.sub.8环烷基-C.sub.1 -C.sub.6烷基链，可能具有以下基团之一作为取代基：C.sub.1 -C.sub.6烷氧羰基，羧基，C.sub.2 -C.sub.6烷酰氧-C.sub.1 -C.sub.6烷基群，氨基-C.sub.1 -C.sub.6烷基群，C.sub.1 -C.sub.6烷基氨基-C.sub.1 -C.sub.6烷基群和羟基-C.sub.1 -C.sub.6烷基群，C.sub.3 -C.sub.8环烷基群，四氢吡喃基-C.sub.1 -C.sub.6烷基群，C.sub.1 -C.sub.3烷二氧基基团取代的C.sub.1 -C.sub.6烷基群，苯基-C.sub.1 -C.sub.6烷基群，在苯环上取代基为1至3个来自C.sub.1 -C.sub.6烷基群和羟基的基团，或者带有C.sub.1 -C.sub.6烷基群作为取代基的哌啶基-C.sub.1 -C.sub.6烷基群；R.sup.2为5-或6-成员饱和或不饱和杂环-C.sub.1 -C.sub.6烷基群，所述杂环选自吡咯啉基、吗啉基、哌啶基、硫代吗啉基、咪唑基、1,2,4-三唑基、呋基、哌嗪基、吡啶基、四氢吡喃基和1,3-氧硫杂环基团，可能具有以下基团之一作为取代基：羟基-C.sub.1 -C.sub.6烷基群，C.sub.2 -C.sub.6烷酰氧-C.sub.1 -C.sub.6烷基群，羟基，C.sub.1 -C.sub.6烷基群，氨基-C.sub.1 -C.sub.6烷基群，C.sub.1 -C.sub.6烷基氨基-C.sub.1 -C.sub.6烷基群，C.sub.1 -C.sub.6烷氧基群，C.sub.1 -C.sub.6烷氧-C.sub.1 -C.sub.6烷氧基群，C.sub.1 -C.sub.6烷氧-C.sub.1 -C.sub.6烷基群，硫基和C.sub.1 -C.sub.6烷基酰胺基团；在碳基喹啉骨架的3-位和4-位之间的碳-碳键为单键或双键，其中药物组合物含有该化合物作为活性成分。
• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020019526A1

  公开（公告）日：2002-02-14

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  一种化合物的结构式，其中R1、R2和R3如上所定义，它们是蛋白酪氨酸激酶的抑制剂，如Janus激酶3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化、类风湿性关节炎、牛皮癣、1型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫疾病的治疗。
• [EN] GROUP 5 METAL COMPLEXES USEFUL FOR AMINE FUNCTIONALIZATION AND SYNTHETIC PROCESS FOR MANUFACTURE THEREOF<br/>[FR] COMPLEXES DE MÉTAUX DU GROUPE 5 UTILES POUR LA FONCTIONNALISATION PAR AMINE ET PROCÉDÉ DE SYNTHÈSE POUR LEUR FABRICATION
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2012040853A1

  公开（公告）日：2012-04-05

  The present invention provides Group 5 metal complexes useful for amine functionalization and synthetic process for manufacture thereof. Provided in this application are halo group 5 metal-amidate complexes having the structure of Formula I: I wherein: M is a group 5 metal, such as Ta, Nb or V; X is a halo substituent, such as CI, F, I or Br; n = 1 or 2,; s = 1 or 2; R1 and R2 are each independently H; a C1 - C25 substituted or unsubstituted, linear, branched or cyclic alkyl; or substituted or unsubstituted aryl or heterocyclic groups; R' is independently a C1 - C25 substituted or unsubstituted, linear, branched or cyclic alkyl; a substituted or unsubstituted aryl; a substituted or unsubstituted heterocyclic group; or NR32; and each R3 is independently a C1 - C25 substituted or unsubstituted, linear, branched or cyclic alkyl; a substituted or unsubstituted aryl; or substituted or unsubstituted heterocyclic group, and a process for synthesis thereof. Also provided are the corresponding metallaaziridine complexes. The metal complex of Formula I, and the corresponding metallaaziridine complex are useful as a catalysts in ct-alkylation of secondary amines and, therefore, also provided are methods of using the metal complex of Formula I, and the corresponding metallaaziridine complex in o-alkylation of secondary amines. This application also provides methods of using the corresponding non-halo group 5 metal-amidate complexes and metallaaziridine complexes in α-alkylation of heterocycles.

  本发明提供了用于胺官能化的五族金属配合物以及其制造的合成方法。本申请提供了具有以下结构的卤素五族金属酰胺配合物，其结构如公式I所示：其中：M为五族金属，如Ta、Nb或V；X为卤素取代基，如Cl、F、I或Br；n = 1或2；s = 1或2；R1和R2各自独立为H；为C1 - C25取代或未取代的线性、支链或环烷基；或取代或未取代的芳基或杂环基；R'独立为C1 - C25取代或未取代的线性、支链或环烷基；取代或未取代的芳基；取代或未取代的杂环基；或NR32；每个R3独立为C1 - C25取代或未取代的线性、支链或环烷基；取代或未取代的芳基；或取代或未取代的杂环基，以及其合成方法。还提供了相应的金属氮杂环丙烷配合物。公式I的金属配合物和相应的金属氮杂环丙烷配合物在次烷胺的α-烷基化中作为催化剂是有用的，因此，还提供了使用公式I的金属配合物和相应的金属氮杂环丙烷配合物在次烷胺的o-烷基化中的方法。本申请还提供了使用相应的非卤素五族金属酰胺配合物和金属氮杂环丙烷配合物在杂环的α-烷基化中的方法。
• MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20190315726A1

  公开（公告）日：2019-10-17

  Disclosed are a novel pyrimidine derivative compound, a pharmaceutically acceptable salt thereof, a method for preparing the compound and a pharmaceutical use of the compound as an anticancer agent or a therapeutic agent for degenerative brain diseases. Specifically, the novel pyrimidine derivative compound has excellent inhibitory activities against kinase enzymes such as ARK5/NUAK1, ACK1, FLT3, JAK1, JAK2 and JAK2 (V617F) and thus is useful for treating and preventing leukemia, ovarian cancer, breast cancer, non-small cell carcinoma, colorectal cancer, glioma, and brain protein abnormalities such as Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia, that is, degenerative diseases caused by Tau deposition.

  本文披露了一种新型嘧啶衍生物化合物，其药用盐，制备该化合物的方法以及将该化合物用作抗癌剂或治疗退行性脑疾病的药用。具体来说，这种新型嘧啶衍生物化合物对激酶酶类如ARK5/NUAK1、ACK1、FLT3、JAK1、JAK2和JAK2(V617F)具有出色的抑制活性，因此可用于治疗和预防白血病、卵巢癌、乳腺癌、非小细胞癌、结直肠癌、胶质瘤以及脑蛋白异常疾病，如阿尔茨海默病、进行性核上性麻痹和颞叶痴呆等由Tau沉积引起的退行性疾病。